Treatment-resistant depression

Greenbrook TMS Announces Preliminary First Quarter 2021 Operational and Financial Results

Tuesday, May 4, 2021 - 9:46pm

b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).

Key Points: 
  • b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).
  • We are proud of our team\xe2\x80\x99s efforts to continue to treat patients suffering from treatment resistant depression and obsessive-compulsive disorder during this difficult time.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.

Using Rapid-Acting Brain Stimulation for Treatment-Resistant Depression - A Free Webinar from the Brain & Behavior Research Foundation

Tuesday, May 4, 2021 - 2:00pm

b'New York, May 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, \xe2\x80\x9cUsing Rapid-Acting Brain Stimulation for Treatment-Resistant Depression\xe2\x80\x9d on Tuesday, May 11, 2021, from 2pm to 3pm ET.

Key Points: 
  • b'New York, May 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, \xe2\x80\x9cUsing Rapid-Acting Brain Stimulation for Treatment-Resistant Depression\xe2\x80\x9d on Tuesday, May 11, 2021, from 2pm to 3pm ET.
  • Past research has demonstrated that a form of FDA-approved non-invasive brain stimulation called rTMS could be optimized to better treat depression as well as other psychiatric disorders.
  • Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation and Host and Executive Producer of the public television series \xe2\x80\x9cHealthy Minds,\xe2\x80\x9d will be the moderator.
  • Join by phone or on the web at bbrf.org/maywebinar.\nThis webinar is part of a series of free monthly \xe2\x80\x9cMeet the Scientist\xe2\x80\x9d webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.

MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms

Wednesday, April 28, 2021 - 9:00am

b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).

Key Points: 
  • b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).
  • In addition, MagVenture TMS Therapy can reduce the symptoms of comorbid anxiety in patients suffering from depression.
  • "\nFor OCD, a 45% response rate was reported for the group receiving treatment, compared to 18% in the sham group.
  • "\nFor subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.\n'

Myconic Capital Corp. Signs Letter of Intent for Acquisition of NY Ketamine Medical Practice, PLLC

Monday, April 5, 2021 - 1:00pm

In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.

Key Points: 
  • In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.
  • Based on the success of its New York City clinic, NY Ketamine Infusions has opened an additional clinic in Long Island, NY (Melville).
  • Dr. Brooks also continues to act as a consultant for privately owned practices in Albany, NY and Madrid, Spain.
  • Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health & wellness sectors.

COMPASS Pathways granted two US patents

Tuesday, March 23, 2021 - 12:00pm

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO).

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO).
  • These patents cover oral formulations of COMPASSs synthetic psilocybin in the treatment of major depressive disorder (MDD), which includes treatment-resistant depression (TRD).
  • These patents are a critical milestone in our efforts to establish a new evidence-based option to help patients with depression in the US, said George Goldsmith, CEO and Co-founder of COMPASS Pathways.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

Treatment-Resistant Depression Market to Rising at a CAGR of 15% Driven by Recent Advancements in Clinical Trials

Thursday, March 11, 2021 - 4:30pm

The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009.
  • For further information on Market Impact by Therapies, visit: Treatment-Resistant Depression (TRD) Market Trends
    Treatment-Resistant Depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options.
  • According to DelveInsight's analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017.

Treatment-Resistant Depression Market to Rising at a CAGR of 15% Driven by Recent Advancements in Clinical Trials

Thursday, March 11, 2021 - 4:30pm

The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009.
  • For further information on Market Impact by Therapies, visit: Treatment-Resistant Depression (TRD) Market Trends
    Treatment-Resistant Depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options.
  • According to DelveInsight's analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017.

MIJ 821: Developed by Novartis for Treatment Resistant Depression - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Thursday, March 11, 2021 - 4:03pm

MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.

Key Points: 
  • MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.
  • "MIJ 821 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Other emerging products for Treatment Resistant Depression are giving market competition to MIJ 821 and launch of late-stage emerging therapies in the near future will significantly impact the market.

Epidemiology Forecast on Treatment-resistant Depression to 2030 - ResearchAndMarkets.com

Friday, December 4, 2020 - 8:48pm

The "Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Treatment-resistant depression epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant depression epidemiology segmented as the Total diagnosed Prevalent of Treatment-resistant depression, Gender-specific cases, Age-specific cases.
  • Quantify patient populations in the global Treatment-resistant depression (TRD) market to improve product design, pricing, and launch plans
    The Treatment-resistant depression (TRD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
    The Treatment-resistant depression (TRD) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies.

The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited to Develop Novel Treatment for Patients with Diverse Psychiatric Disorders

Friday, October 30, 2020 - 12:00pm

The agreement will support the clinical development of therapeutics for patients living with a broad range of psychiatric disorders including treatment-resistant depression (TRD).

Key Points: 
  • The agreement will support the clinical development of therapeutics for patients living with a broad range of psychiatric disorders including treatment-resistant depression (TRD).
  • Rugens proprietary technology stems from its novel research into the circuit mechanisms of psychiatric disorders, facilitated by genetic-based animal models.
  • This research has translated into its innovative drug candidate, which has potentially broad application across multiple psychiatric indications.
  • Rugen Holdings (Cayman) Limited, dba Rugen Therapeutics is a biotech company discovering and developing novel, first-in-class, small-molecule drugs with the potential to address multiple psychiatric indications.